Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...
This agent, however, may be used as monotherapy in selected patients who have contraindications for steroid treatment. Peripheral neuropathy is under-reported at diagnosis in patients with ...
Peripheral neuropathy is a complex and often debilitating condition that affects millions of people worldwide. Research estimates around 10% of the general population experiences some form of ...
Some diseases producing liver dysfunction can independently cause peripheral neuropathy. Hence, a cause and effect relationship between liver disease and neuropathy has been questioned.
The causal relationship of liver disease to neuropathy has been questioned. This study was designed to evaluate the incidence and character of peripheral neuropathy in patients with liver cirrhosis.
- The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical ...
Aachen, Germany, & Morristown, N.J., 7 November 2024 (News Aktuell) – Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical ...